Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines (Q84140441)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20433991%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20433991%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

venous thromboembolism

1 reference

Gary H Lyman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20433991%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Nicole M Kuderer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20433991%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

American Society of Clinical Oncology

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20433991%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

1 April 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20433991%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20433991%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

125 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20433991%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

S120-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20433991%20AND%20SRC:MED&resulttype=core&format=json

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Incidence of venous thromboembolism and its effect on survival among patients with common cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Thromboembolism in hospitalized neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Venous thromboembolism in patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Venous thromboembolism in the hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Thrombotic events in patients with cancer receiving antiangiogenesis agents

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Development and validation of a predictive model for chemotherapy-associated thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Assessing risk of venous thromboembolism in the patient with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Incidence of venous thromboembolism and the impact on survival in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Impact of venous thromboembolism and anticoagulation on cancer and cancer survival

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Prognosis of Cancers Associated with Venous Thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Outcomes and cost of deep venous thrombosis among patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Anticoagulation in the treatment of established venous thromboembolism in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

New antithrombotic drugs: potential for use in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Prevention of venous thromboembolism in hospitalized patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Prevention of venous thromboembolism in the cancer surgical patient

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Prevention of thrombosis in ambulatory patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Thromboprophylaxis rates in US medical centers: success or failure?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Venous thrombosis in cancer patients: insights from the FRONTLINE survey

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Venous thromboembolism in patients with active cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

The heparins and cancer: review of clinical trials and biological properties

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Management of venous thromboembolism in cancer patients: ESMO clinical recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

American Society of Clinical Oncology 2007 Clinical Practice Guideline Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Incidence of venous thromboembolism in patients hospitalized with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Thalidomide therapy and deep venous thrombosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Thromboprophylaxis in malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Deep vein thrombosis of the leg. Is there a "high risk" group?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Treatment of deep-vein thrombosis with intermittent streptokinase and plasminogen infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Does prolonged thromboprophylaxis improve outcome in patients undergoing surgery?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Complications of therapy for venous thromboembolic disease in patients with brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Therapy of venous thromboembolism in patients with brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Clinical practice. Treatment of deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

The effect of low molecular weight heparin on survival in patients with advanced malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970029-3

7 January 2021

10.1016/S0049-3848(10)70029-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20433991%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference